Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immunology Leads Shire's 2017 Sales Growth With Addition Of HAE Portfolio

Executive Summary

Immunology portfolio yielded 14% sales growth in 2017, led by growing subcutaneous immunoglobulins and a still-rising HAE franchise. Dry eye drug Xiidra was another 2017 growth catalyst.
Advertisement

Related Content

Allergan, Shire Battle In Dry Eye As Generics Advance
Shire May Split Up – But Punting On Bigger Decisions For Now
Roche's Hemlibra Priced And Labeled To Beat Competition, Safety Concern
Shire Sees Another Way To Compete With CSL Behring In HAE With New Version Of Cinryze
Shire CEO Says Lanadelumab Results Vindicate Dyax Buy, M&A Strategy
Shire & Baxalta Seal The Deal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100404

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel